Journal Article

Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection

Curry, Michael P, Bansal, Meena B, McHutchison, John G, Ramji, Alnoor, Reddy, K. Rajender, Subramanian, G. Mani, Huang, K.C, Flamm, Steven L, Cooper, Curtis L, Dvory-Sobol, Hadas, Younes, Ziad H, Verna, Elizabeth C, Strasser, Simone I, Tran, Tram T, de Lédinghen, Victor, Landis, Charles S, Hyland, Robert H, Stamm, Luisa M, Brainard, Diana M, Pianko, Stephen, Kowdley, Kris V, Svarovskaia, Evguenia, Gordon, Stuart C, Buggisch, Peter, Manns, Michael P, Tong, Myron, Zhang, Jie, Bourlière, Marc, Schiff, Eugene R, Ravendhran, Natarajan, Vierling, John M, Zeuzem, Stefan

2017

Overview

In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with sofosbuvir, velpatasvir, and voxilaprevir achieved high rates of sustained virologic response. The majority of patients who are chronically infected with hepatitis C virus (HCV) can now be successfully treated with drugs that directly target viral replication. 1 , 2 Combination regimens of direct-acting antiviral agents (DAAs) provide rates of sustained virologic response exceeding 90%, regardless of HCV genotype, disease stage, or treatment history. 3 The proportion of patients who do not have a sustained virologic response to treatment with approved regimens is small, but given the size of the infected population — estimates range up to 150 million people worldwide 4 — the absolute number of such patients is substantial and will increase as more . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Aged / Aged, 80 and over / Aminoisobutyric Acids / Antiretroviral drugs / Antiviral agents / Antiviral Agents - adverse effects / Antiviral Agents - therapeutic use / Antiviral drugs / Carbamates - adverse effects / Carbamates - therapeutic use / Cirrhosis / Clinical trials / Cyclopropanes / Diarrhea / Drug Combinations / Drug Resistance, Viral / Drug therapy / Fatigue / Female / Genotype / Genotypes / Headache / Hepacivirus - drug effects / Hepacivirus - genetics / Hepatitis / Hepatitis C - complications / Hepatitis C - drug therapy / Hepatitis C - virology / Heterocyclic Compounds, 4 or More Rings - adverse effects / Heterocyclic Compounds, 4 or More Rings - therapeutic use / Human health and pathology / Humans / Lactams, Macrocyclic / Leucine - analogs & derivatives / Life Sciences / Liver cirrhosis / Liver Cirrhosis - etiology / Macrocyclic Compounds - adverse effects / Macrocyclic Compounds - therapeutic use / Male / Middle Aged / Nausea / Pharmaceuticals / Proline - analogs & derivatives / Protease Inhibitors - therapeutic use / Proteinase / Quinoxalines / Sofosbuvir - adverse effects / Sofosbuvir - therapeutic use / Sulfonamides - adverse effects / Sulfonamides - therapeutic use / Viral Nonstructural Proteins - antagonists & inhibitors